Dishman Carbogen Amcis
BSE: 540701 | NSE: DCAL | ISIN: INE385W01011 | SECTOR: Biotechnology & DrugsOpen
233.90High
238.20Low
230.60Prev Close
233.90P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
37.16BVolume
37.44KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
235.60Ask
237.00
Company Description
- Biotechnology & Drugs
BSE
540701NSE
DCALISIN
INE385W01011
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Company’s segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.
Company Officers
Harshil Dalal
Global Chief Financial OfficerShrima Dave
Compliance Officer, Company SecretaryArpit Vyas
Global Managing Director, Executive DirectorDeohooti Vyas
Whole-Time Director